Javascript must be enabled to continue!
Catalytic Wittig and aza-Wittig reactions
View through CrossRef
This review surveys the literature regarding the development of catalytic versions of the Wittig and aza-Wittig reactions. The first section summarizes how arsenic and tellurium-based catalytic Wittig-type reaction systems were developed first due to the relatively easy reduction of the oxides involved. This is followed by a presentation of the current state of the art regarding phosphine-catalyzed Wittig reactions. The second section covers the field of related catalytic aza-Wittig reactions that are catalyzed by both phosphine oxides and phosphines.
Title: Catalytic Wittig and aza-Wittig reactions
Description:
This review surveys the literature regarding the development of catalytic versions of the Wittig and aza-Wittig reactions.
The first section summarizes how arsenic and tellurium-based catalytic Wittig-type reaction systems were developed first due to the relatively easy reduction of the oxides involved.
This is followed by a presentation of the current state of the art regarding phosphine-catalyzed Wittig reactions.
The second section covers the field of related catalytic aza-Wittig reactions that are catalyzed by both phosphine oxides and phosphines.
Related Results
Azacitidine-panobinostat activates NF-kb signaling in the bone marrow microenvironment to chemosensitize KMT2A rearranged pediatric AML
Azacitidine-panobinostat activates NF-kb signaling in the bone marrow microenvironment to chemosensitize KMT2A rearranged pediatric AML
Abstract
KMT2A rearrangements (KMT2Ar), a hallmark of pediatric acute leukemia, are present in 20% of pediatric acute my...
Evaluation Of Acadesine, a Drug Stimulating Cell Autophagy, In Azacitidine(AZA)-Resistant Myelodysplastic Syndromes (MDS)
Evaluation Of Acadesine, a Drug Stimulating Cell Autophagy, In Azacitidine(AZA)-Resistant Myelodysplastic Syndromes (MDS)
Abstract
Background
AZA is currently the first line treatment for intermediate-2 and high-risk IPSS myelodysplastic syndromes (M...
An unusual adverse event of azathioprine: Cutaneous small vessel vasculitis
An unusual adverse event of azathioprine: Cutaneous small vessel vasculitis
In this article, we present a Japanese female case of cutaneous small vessel vasculitis (CSVV) after administration of oral azathioprine (AZA).
A 56-year-old Japanese woman with l...
Modulation of CD81 By Epigenetic Drug Combination Sensitizes Acute Lymphoblastic Leukemia Via Decreased BTK Signaling
Modulation of CD81 By Epigenetic Drug Combination Sensitizes Acute Lymphoblastic Leukemia Via Decreased BTK Signaling
Background
We previously discovered that the epigenetic drug combination - azacitidine (aza, DNMTi) and panobinostat (pano, HDACi) can sensitize ALL cells to chemoth...
pVAX14 DNA, An Immunoadjuvant, Extends Life-Span As Add-On Treatment To Azacitidine (AZA) In A Mouse Model Of High Risk Myelodysplastic Syndrome (HR-MDS)
pVAX14 DNA, An Immunoadjuvant, Extends Life-Span As Add-On Treatment To Azacitidine (AZA) In A Mouse Model Of High Risk Myelodysplastic Syndrome (HR-MDS)
Abstract
Background
We have established animal models of MDS and acute myelogenous leukemia (AML) using NRASD12 and overexpressi...
Heterotricyclodecane. XXIV. 2‐Aza‐7‐oxa‐twistane (bzw. 2‐Oxa‐7‐aza‐twistane) und 2‐Aza‐7‐oxa‐isotwistane
Heterotricyclodecane. XXIV. 2‐Aza‐7‐oxa‐twistane (bzw. 2‐Oxa‐7‐aza‐twistane) und 2‐Aza‐7‐oxa‐isotwistane
2‐Aza‐7‐oxa‐twistanes (or 2‐oxa‐7‐aza‐twistanes, respectively)Die nicht mit den IUPAC‐Regeln übereinstimmende Numerierung (b): 2‐Aza‐7‐oxa‐twistane, Substituent an C(10) (vgl. Korr...
PTU-075 Long Term outcome of Azathioprine Therapy in 353 Consecutive IBD Patients
PTU-075 Long Term outcome of Azathioprine Therapy in 353 Consecutive IBD Patients
Introduction
Thiopurines are the mainstay of therapy in Inflammatory Bowel Disease (IBD). Azathioprine (AZA) and Mercaptopurine are very effective at maintaining ...
5-Azacytidine Versus Intensive Chemotherapy or BSC in Elderly (>60 years) Acute Myeloid Leukemia Patients. A Retrospective Analysis
5-Azacytidine Versus Intensive Chemotherapy or BSC in Elderly (>60 years) Acute Myeloid Leukemia Patients. A Retrospective Analysis
Abstract
Abstract 2612
BACKGROUND:
5-Azacytidine (AZA) has proven to prolong overall survival (OS) in higher-risk...

